Context Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein
overexpressed in most prostate cancers and exploited as a target for PSMA-targeted …

Targeted protein degradation (TPD) has emerged as a revolutionary paradigm in drug
discovery and development, offering a promising avenue to tackle challenging therapeutic …

Combined radiotherapy (RT) and chemotherapy are prescribed to patients with advanced
prostate cancer (PCa) to increase their survival; however, radiation-related side effects and …

Monomethyl auristatin E (MMAE) is a potent tubulin inhibitor that is used as the payload for
four FDA-approved antibody–drug conjugates (ADC). Deconjugated MMAE readily diffuses …

Active targeting to cancer involves exploiting specific interactions between receptors on the
surface of cancer cells and targeting moieties conjugated to the surface of vectors such that …

Prostate cancer is the second most common type of cancer among men. Its main method of
treatment is chemotherapy, which has a wide range of side effects. One of the solutions to …

We report a new 1–6 self-immolative, traceless crosslinker derived from the natural product
gallic acid. The linker acts through a pH-dependent mechanism for drug release. This 5 …

Background Male dogs can develop spontaneous prostate cancer, which is similar
physiologically to human disease. Recently, Tweedle and coworkers have developed an …

Most patients with advanced prostate cancer (PCa) will develop metastatic castration-
resistant prostate cancer (mCRPC) after androgen deprivation therapy, at this time the tumor …

The non-selective cytotoxicity of toxins limits the clinical relevance of the toxins. In recent
years, toxins have been widely used as warheads for antibody‒drug conjugates (ADCs) …